Clinical Trial

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Name: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma — clinical trial record (NCT03628209)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and efficacy of nivolumab, or nivolumab in combination with azacitidine in participants with recurrent, resectable osteosarcoma

Protocol Amendment History 1 change

minor Completion pushed: 2026-04 -> 2027-04 2026-07-31

Trial Details

NCT Number	NCT03628209
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: Bristol-Myers Squibb
Conditions	Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Enrollment	21 participants
Start Date	2019-10-03
Primary Completion	2024-12-29 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-30